Evofem Biosciences, Inc. (EVFM) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Net income	-8.6	-2.4	-11.5	89.5	-124.1	-32.0	-52.6	-74.1
Depreciation and amortization	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3
Asset impairment charges			-0.3
Stock-based compensation	0.3	0.4	0.2	1.0	1.1	1.1	1.4	1.1
Change in working capital [+]	4.6	-2.2	5.6	0.2	-4.3	5.9	15.0	5.4
Accounts receivable	2.2	-6.3	11.6	-5.5	-2.9	2.0	-2.4	-0.9
Inventories	1.8	-0.1	-0.9	1.0	0.8	0.8	1.9	0.8
Other current assets	0.9	1.5	0.6	4.7	-1.7	-1.0	13.4	3.0
Accounts payable	-1.6	3.8	0.4	-0.7	1.0	3.7	3.2	-0.4
Accrued expenses	1.2	-0.4	-3.5	1.3	-1.8	-0.1	-0.5	2.0
Other	0.2	-0.8	-2.7	-0.6	0.3	0.5	-0.6	1.0
Other operating activities	2.0	-1.1	-0.8	-107.2	100.4	3.8	14.7	29.9
Cash from operations	-1.5	-4.9	-6.5	-16.3	-26.7	-20.9	-21.3	-37.4

Capital expenditures	0.0	0.0	0.0	-0.1	-0.2	-0.1	-0.1	-0.6
Purchases of property and equipment	0.0	0.0	0.0	-0.1	-0.2	-0.1	-0.1	-0.6
Cash from investing	0.0	0.0	0.0	-0.1	-0.2	-0.1	-0.1	-0.6

Repurchase of common stock, net					0.0
Option exercises					0.0		0.1
Financing costs			-1.2		-0.5	-0.4	-1.0
Other cash from financing	0.6	1.7	0.3	3.9	40.9	14.8	9.0	0.0
Cash from financing	0.6	1.7	1.5	3.9	41.4	15.1	9.9	0.0

Free cash flow	-1.5	-4.9	-6.6	-16.4	-26.8	-21.0	-21.3	-38.0
Per share (diluted)	($0.95)	($3.89)	($0.11)	($0.03)	($123.62)	($236.47)	($2.44)	($3.69)